AVBPClinical Trial Completion
ClinicalTrials.gov primary completion watch
ArriVent BioPharma | Furmonertinib | EGFR-mutant NSCLC
Catalyst details
Primary completion date tracked from linked public trial record.
Phase
Phase 3
Expected date
2026-12-15
Expected period
December 2026
Source type
clinicaltrials.gov
monthactive
Source URLNotes
This record is structured for public-source tracking and manual analyst override. The database stores date confidence separately from exact dates so quarter, half-year, and estimated guidance can be handled without inventing precision.
Open company detail